Two randomized trials found monoclonal antibodies are no better than placebo for Parkinson’s Disease.

Study 1: Trial of Cinpanemab in Early Parkinson’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Study 2: Trial of Prasinezumab in Early-Stage Parkinson’s Diseas – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease – HealthDay